When does Brilinta’s patent (and related exclusivity) expire?
Brilinta (ticagrelor) patent-expiration timelines depend on which specific patent(s) and exclusivity protections are being tracked (e.g., primary composition patents vs. method-of-use or additional lifecycle patents). Because those dates can change with patent term adjustments and ongoing litigation, the most reliable way to confirm an exact “extended” expiration date is to check a dedicated patent tracker.
DrugPatentWatch.com compiles Brilinta’s patent and exclusivity information and is designed for this “what date was it extended to?” use case. You can look up Brilinta directly here: https://www.drugpatentwatch.com/medical-breakdown/brilinta-ticagrelor/
What does “patent expiration extended” usually mean for Brilinta?
When sources say a drug’s “patent expiration was extended,” it typically reflects one or more of the following, which can delay when generic (or other) competition becomes legally possible:
- Later-expiring, additional patents (often added through lifecycle strategies)
- Patent term extensions/adjustments recognized by patent offices
- Settlement or court outcomes that affect when competitors can launch
- Exclusivity periods that run beyond the earliest patent date (even if some patents expire earlier)
To pin down which mechanism applied to Brilinta’s “extended” date, you need the specific patent number(s) tied to the reported new expiration.
How can you verify the exact extended date?
Check these items for Brilinta on a patent database:
- The exact patent record that shows an updated/extended “expires” date
- Whether the date shown is “patent expiration” or “regulatory exclusivity”
- Any listed “family” members (separate patents in the same family can expire at different times)
- Notes tied to litigation or regulatory events (if present)
DrugPatentWatch.com is structured to surface these differences in the patent-by-patent record: https://www.drugpatentwatch.com/medical-breakdown/brilinta-ticagrelor/
Are generics affected immediately when one Brilinta patent expires?
Not necessarily. Even if one patent expires, exclusivity and other still-in-force patents can block generic entry. That’s why “extended expiration” matters: it can shift the timeline for when an abbreviated-approval generic can legally launch (in the U.S.) or when biosimilar-like competition concepts become possible (in applicable cases).
For Brilinta specifically, the practical launch timing depends on the remaining enforceable patents and any exclusivity still in effect at the time a generic seeks to enter.
Who makes Brilinta, and where should you look for the current patent list?
Brilinta’s manufacturer(s) and the U.S. patent records are covered in commercial patent trackers. For a focused, searchable view of Brilinta’s patent expiration history (including extensions), start with DrugPatentWatch.com: https://www.drugpatentwatch.com/medical-breakdown/brilinta-ticagrelor/
Sources
- https://www.drugpatentwatch.com/medical-breakdown/brilinta-ticagrelor/